Seattle Genetics committed $5m to the round earlier this week when the two companies signed a partnership agreement.
US-based biotechnology company Unum Therapeutics closed a $65m series B round today featuring biotechnology company Seattle Genetics, which committed $5m earlier this week as part of a partnership agreement.
The round featured pharmaceutical company Novo; Sanofi-Genzyme BioVentures, the corporate venturing arm of pharmaceutical company Sanofi; and Brace Pharma Capital, the investment vehicle of pharmaceutical company EMS.
New Leaf Venture Partners led the oversubscribed round which also included Cowen Private Investments, Jennison Associates, Sabby Management, Sectoral Asset Management, Wellington Management Company, Fidelity Biosciences and…